Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Gastric Ulcers Treatment Pipeline Review H2 2016

Friday, October 14, 2016 3:28
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Gastric Ulcers – Pipeline Review, H2 2016’, provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers 
- The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Gastric Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Gastric Ulcers Overview 6 
Therapeutics Development 7 
Pipeline Products for Gastric Ulcers – Overview 7 
Gastric Ulcers – Therapeutics under Development by Companies 8 
Gastric Ulcers – Pipeline Products Glance 9 
Clinical Stage Products 9 
Early Stage Products 10 
Gastric Ulcers – Products under Development by Companies 11 
Gastric Ulcers – Companies Involved in Therapeutics Development 12 
Ache Laboratorios Farmaceuticos S/A 12 
Astellas Pharma Inc. 13 
ChoDang Pharm Co., Ltd. 14 
Kukje Pharmaceutical Industry Co., Ltd. 15 
XuanZhu Pharma Co., Ltd. 16 
Gastric Ulcers – Therapeutics Assessment 17 
Assessment by Monotherapy Products 17 
Assessment by Combination Products 18 
Assessment by Target 19 
Assessment by Mechanism of Action 21 
Assessment by Route of Administration 23 
Assessment by Molecule Type 24 
Drug Profiles 25 
(ecabet + ranitidine) – Drug Profile 25 
Product Description 25 
Mechanism Of Action 25 
R&D Progress 25 
anaprazole sodium – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
ASP-6537 – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
KJ-14001 – Drug Profile 28 
Product Description 28 
Mechanism Of Action 28 
R&D Progress 28 
PDI-39 – Drug Profile 29 
Product Description 29 
Mechanism Of Action 29 
R&D Progress 29 
PMKS-005 – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
Small Molecules for Gastric Ulcers – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
Gastric Ulcers – Dormant Projects 32 
Gastric Ulcers – Discontinued Products 33 
Gastric Ulcers – Product Development Milestones 34 
Featured News & Press Releases 34 
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 34 
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 35 
Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 35 
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 35 
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 36 
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 37 
Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court 37 
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 38 
Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals 38 
Oct 23, 2001: Prilosec US litigation 39 
May 02, 2001: Astrazeneca Receives Six Months’ Market Exclusivity for Prilosec 39 
May 02, 2001: Court Denies Generic’s Application for Summary Judgement on Prilosec Patent 39 
Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement 39 
Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada 40 
Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy 40 
Appendix 42 
Methodology 42 
Coverage 42 
Secondary Research 42 
Primary Research 42 
Expert Panel Validation 42 
Contact Us 42 
Disclaimer 43

List of Tables 
Number of Products under Development for Gastric Ulcers, H2 2016 7 
Number of Products under Development by Companies, H2 2016 8 
Comparative Analysis by Clinical Stage Development, H2 2016 9 
Comparative Analysis by Early Stage Development, H2 2016 10 
Products under Development by Companies, H2 2016 11 
Gastric Ulcers – Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 12 
Gastric Ulcers – Pipeline by Astellas Pharma Inc., H2 2016 13 
Gastric Ulcers – Pipeline by ChoDang Pharm Co., Ltd., H2 2016 14 
Gastric Ulcers – Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 15 
Gastric Ulcers – Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 16 
Assessment by Monotherapy Products, H2 2016 17 
Assessment by Combination Products, H2 2016 18 
Number of Products by Stage and Target, H2 2016 20 
Number of Products by Stage and Mechanism of Action, H2 2016 22 
Number of Products by Stage and Route of Administration, H2 2016 23 
Number of Products by Stage and Molecule Type, H2 2016 24 
Gastric Ulcers – Dormant Projects, H2 2016 32 
Gastric Ulcers – Discontinued Products, H2 2016 33

Get this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.